
|Videos|June 3, 2022
Dr. Jonasch on long-term efficacy and safety with belzutifan in renal cell carcinoma
Author(s)Urology Times staff
“This analysis has a median follow-up of 41 months,” says Jonasch.
Advertisement
In this video, Eric Jonasch, MD, discusses the results from 2022 ASCO Annual Meeting abstract 4509, “Phase 1 LITESPARK-001 (MK-6482-001) study of the HIF-2α inhibitor belzutifan in advanced solid tumors: Update of the clear cell renal cell carcinoma (ccRCC) cohort with more than 3 years of total follow-up.” Jonasch is a professor in the Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Study launches of MRI plus PSMA-PET imaging for prostate cancer detection
2
Initial ARID results published in World Journal of Urology as pivotal trial progresses
3
New Data Influencing your Treatment Decisions in mCSPC
4
CREST and POTOMAC: Redefining immunotherapy’s role in NMIBC
5



















